[go: up one dir, main page]

NO20001515L - Vitronektin reseptor-antagonist - Google Patents

Vitronektin reseptor-antagonist

Info

Publication number
NO20001515L
NO20001515L NO20001515A NO20001515A NO20001515L NO 20001515 L NO20001515 L NO 20001515L NO 20001515 A NO20001515 A NO 20001515A NO 20001515 A NO20001515 A NO 20001515A NO 20001515 L NO20001515 L NO 20001515L
Authority
NO
Norway
Prior art keywords
receptor antagonist
vitronectin receptor
vitronectin
osteoporosis
useful
Prior art date
Application number
NO20001515A
Other languages
English (en)
Other versions
NO20001515D0 (no
Inventor
William E Bondinelli
Original Assignee
Smithkline Beecham Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Smithkline Beecham Corp filed Critical Smithkline Beecham Corp
Publication of NO20001515D0 publication Critical patent/NO20001515D0/no
Publication of NO20001515L publication Critical patent/NO20001515L/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Rheumatology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Cardiology (AREA)
  • Vascular Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Urology & Nephrology (AREA)
  • Oncology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

En forbindelse med formel (I) er beskrevet som er en vitronektin-reseptorantagonist og er nyttige ved behandling av osteoporose: eller et farmasøytisk godtagbart salt derav.
NO20001515A 1997-09-24 2000-03-23 Vitronektin reseptor-antagonist NO20001515L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US5986797P 1997-09-24 1997-09-24
PCT/US1998/019987 WO1999015178A1 (en) 1997-09-24 1998-09-24 Vitronectin receptor antagonist

Publications (2)

Publication Number Publication Date
NO20001515D0 NO20001515D0 (no) 2000-03-23
NO20001515L true NO20001515L (no) 2000-03-23

Family

ID=22025805

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20001515A NO20001515L (no) 1997-09-24 2000-03-23 Vitronektin reseptor-antagonist

Country Status (13)

Country Link
EP (1) EP1023073A1 (no)
JP (1) JP2002500162A (no)
KR (1) KR20010024249A (no)
CN (1) CN1271284A (no)
AU (1) AU9578798A (no)
BR (1) BR9813214A (no)
CA (1) CA2304000A1 (no)
HU (1) HUP0003931A2 (no)
IL (1) IL135188A0 (no)
NO (1) NO20001515L (no)
PL (1) PL339414A1 (no)
TR (1) TR200000786T2 (no)
WO (1) WO1999015178A1 (no)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000046215A1 (en) 1999-02-03 2000-08-10 Merck & Co., Inc. Benzazepine derivatives as alpha-v integrin receptor antagonists
US6514964B1 (en) 1999-09-27 2003-02-04 Amgen Inc. Fused cycloheptane and fused azacycloheptane compounds and their methods of use
AU2002316855B2 (en) 2001-04-24 2008-03-13 Merck Patent Gmbh Combination therapy using anti-angiogenic agents and TNFalpha
KR20040058229A (ko) 2001-10-22 2004-07-03 더 스크립스 리서치 인스티튜트 항체 표적화 화합물
JP2006522139A (ja) 2003-04-04 2006-09-28 スミスクライン・ビーチャム・コーポレイション ベンズアゼピンの製造方法およびその中間体
WO2005075655A2 (en) 2004-02-02 2005-08-18 Pioneer Hi-Bred International, Inc. Ap2 domain transcription factor odp2 (ovule development protein 2) and methods of use
UA87854C2 (en) 2004-06-07 2009-08-25 Мерк Энд Ко., Инк. N-(2-benzyl)-2-phenylbutanamides as androgen receptor modulators
KR20080089489A (ko) 2006-01-18 2008-10-06 메르크 파텐트 게엠베하 인테그린 리간드를 사용하는 암치료용 특이적 요법
US20100069302A1 (en) 2007-07-18 2010-03-18 Stefan Krueger Specific therapy and medicament using integrin ligands for treating cancer
ES2428896T3 (es) 2007-11-16 2013-11-12 Ube Industries, Ltd. Compuesto de benzacepinona
WO2009111679A2 (en) * 2008-03-06 2009-09-11 Smithkline Beecham Corporation Process
EP2395992A2 (en) 2009-02-10 2011-12-21 The Scripps Research Institute Chemically programmed vaccination
JPWO2010113958A1 (ja) 2009-03-30 2012-10-11 宇部興産株式会社 眼の疾患の治療又は予防のための医薬組成物
SG176103A1 (en) 2009-05-25 2011-12-29 Merck Patent Gmbh Continuous administration of cilengitide in cancer treatments
EP2529018B1 (en) 2009-12-30 2016-06-22 Pioneer Hi-Bred International, Inc. Methods and compositions for the introduction and regulated expression of genes in plants
AU2010339481B2 (en) 2009-12-30 2016-02-04 Pioneer Hi-Bred International, Inc. Methods and compositions for targeted polynucleotide modification
JP6649902B2 (ja) 2014-05-30 2020-02-19 ファイザー・インク 選択的アンドロゲン受容体モジュレーターとしてのカルボニトリル誘導体
WO2023275715A1 (en) 2021-06-30 2023-01-05 Pfizer Inc. Metabolites of selective androgen receptor modulators

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
UA60311C2 (uk) * 1996-10-02 2003-10-15 Смітклайн Бічам Корпорейшн Антагоністи рецептора вітронектину, спосіб одержання цих сполук та фармацевтична композиція

Also Published As

Publication number Publication date
NO20001515D0 (no) 2000-03-23
BR9813214A (pt) 2000-08-29
TR200000786T2 (tr) 2000-08-21
AU9578798A (en) 1999-04-12
WO1999015178A1 (en) 1999-04-01
IL135188A0 (en) 2001-05-20
HUP0003931A2 (hu) 2001-10-28
KR20010024249A (ko) 2001-03-26
CN1271284A (zh) 2000-10-25
JP2002500162A (ja) 2002-01-08
CA2304000A1 (en) 1999-04-01
PL339414A1 (en) 2000-12-18
EP1023073A1 (en) 2000-08-02

Similar Documents

Publication Publication Date Title
NO20001515L (no) Vitronektin reseptor-antagonist
NO20001514L (no) Vitronectin-reseptor-antagonist
NO983002L (no) Vitronectin-reseptor-antagonister
NO983003L (no) Vitronectin-reseptor-antagonister
NO20025821L (no) 2-aminokarbonyl-9H-purinderivater
EP1019045A4 (en) ANTITHROMBOTIC AGENTS
ATE306261T1 (de) Antithrombosemittel
EP0896533A4 (en) PENTAFLUOROBENZEN SULPHONAMIDES AND ANALOGS
FI964815A0 (fi) Piperatsiinijohdoksia 5-HT1A antagonisteina
DK0894084T3 (da) Kanelsyrederivater og deres anvendelse som integrinantagonister
SG44989A1 (en) Crystalline hydrochloride of (R)-(-)-2-{N-[4-(1,1-dioxid-3-oxo-2,3-dihydro-benzisothiazol-2-yl)-butyl]-aminomethyl}-chroman
AU2002213421A1 (en) Condensed pyridoindole derivatives
BR9812340A (pt) Antagonistas de receptor de vitronectina
NO975975L (no) Vitronektinreseptor-antagonister, fremstilling samt anvendelse derav
ATE240339T1 (de) Nukleotidanaloga
DK1468689T3 (da) 2-methyl-thieno-benzodiazepine formulation
AP1534A (en) Vitronectin receptor antagonists.
NO974400L (no) Kombinasjonspreparater inneholdende benazepril eller benazeprilat og valsartan
WO1998031704A3 (en) Tachykinin antagonists
WO2001017959A3 (en) Vitronectin receptor antagonists
NO20004545D0 (no) FremgangsmÕte for fremstilling av (R)-<alfa>-(2,3- dimetoksyfenyl)-1-[2-(4-fluorofenyl)etyl]-4-piperidinmetanol
WO2000007544A3 (en) Vitronectin receptor antagonists
DK0980383T3 (da) Farmaceutisk acceptable salte af 3-hydroxy-østr-5(10)-en-17-on-3-sulfat aktive som østrogener
NO306673B1 (no) Mellomprodukt for fremstilling av farmasöytisk aktiv forbindelse
IT1303687B1 (it) Impiego dell'acido gammaidrossibutirrico o di un suo salefarmaceuticamente accettabile per il trattamento dell'ischemia

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application